[144] Alnylam Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Alnylam Pharmaceuticals (ALNY) Form 144 summary: This notice reports the proposed sale of 11,250 shares of common stock acquired and to be sold on 08/18/2025. The shares were acquired the same day by exercise of stock options from the issuer and paid in cash. The broker listed is UBS Financial Services, Inc., 11 Madison Avenue, New York. The aggregate market value of the shares at the time of this filing is reported as $5,062,500.00. The filing states the issuer has 131,079,015 shares outstanding and names NASDAQ as the exchange. The filer reports "Nothing to Report" for securities sold by the person in the past three months. The filer also certifies they are not aware of undisclosed material adverse information.

Positive

• Transaction fully documented: Broker, acquisition method, payment type, and aggregate market value are disclosed
• No prior sales reported: The filer reports "Nothing to Report" for securities sold in the past three months

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine insider exercise and immediate sale of equity; not a company-level operational disclosure.

The filing documents a same-day exercise of stock options for 11,250 shares and a proposed sale with an aggregate market value of $5.06M. For investors, this is a liquidity event by an insider or option-holder rather than new information about business performance. The absence of reported sales in the prior three months indicates this transaction is discrete rather than part of frequent disposal activity. No financial results, guidance, or new contracts are disclosed here, so market impact is likely limited unless coincident with other material disclosures.

Compliance / Corporate Governance Analyst

TL;DR: Filing appears procedurally complete for a Rule 144 notice tied to option exercise and sale.

The form identifies the broker, nature of acquisition as exercise of stock options, payment in cash, and certifies no undisclosed material adverse information. It also lists the issuer's outstanding shares and exchange. The statement "Nothing to Report" for prior three-month sales simplifies aggregation requirements. From a compliance perspective, required transactional details are present; no indications of relief, exemptions, or trading plan dates are provided on the face of the form.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Avenue 4th Floor New York NY 10010	11250	5062500.00	131079015	08/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2025	Exercise of stock options	Issuer			11250	08/18/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ALNY Form 144 say was acquired and sold?

The filing reports the proposed sale of 11,250 common shares acquired by exercise of stock options and to be sold on 08/18/2025.

What broker handled the proposed sale on the Form 144 for ALNY?

The broker listed is UBS Financial Services, Inc., 11 Madison Avenue, 4th Floor, New York, NY 10010.

What aggregate value and exchange are reported in the Form 144 for ALNY?

The aggregate market value reported is $5,062,500.00 and the exchange named is NASDAQ.

Were there any other securities sold by the filer in the past three months according to the Form 144?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

How was the purchase paid according to the Form 144?

The filing indicates payment was made in cash for the exercised options and resulting shares.